(2S)-6-(tert-butoxycarbonylamino)-2-(cyclopentanecarbonylamino)hexanoic acid | 75691-94-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-6-(tert-butoxycarbonylamino)-2-(cyclopentanecarbonylamino)hexanoic acid
• 英文别名: N-alpha-cyclopentanecarbonyl-N-epsilon-tert-butyl-oxycarbonyl-L-lysine；(2S)-2-(cyclopentanecarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid
• CAS: 75691-94-0
• 化学式: C₁₇H₃₀N₂O₅
• 分子量: 342.436
• InChiKey: SOQKDPZZWCTXMY-ZDUSSCGKSA-N

物化性质

• 熔点：
  104.5-105.5 °C(Solv: ethyl ether (60-29-7); hexane (110-54-3))
• 沸点：
  581.3±50.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  24
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S)-6-(tert-butoxycarbonylamino)-2-(cyclopentanecarbonylamino)hexanoic acid 生成 N-alpha-cyclopentanecarbonyl-N-epsilon-tert-butyloxy-carbonyl-L-lysine-N-hydroxysuccinimide ester
  参考文献：
  名称：

  RYAN, JAMES W.;CHUNG, ALFRED

  摘要：

  DOI：
• 作为产物：
  描述：

  succinimidyl cyclopentanecarboxylate 生成 (2S)-6-(tert-butoxycarbonylamino)-2-(cyclopentanecarbonylamino)hexanoic acid
  参考文献：
  名称：

  RYAN, JAMES W.;CHUNG, ALFRED

  摘要：

  DOI：

文献信息

• Orally effective anti-hypertensive agents
  申请人：University of Miami

  公开号：US04745124A1

  公开（公告）日：1988-05-17

  Novel thiolester compounds are disclosed which are orally effective angiotensin converting enzyme inhibitors useful in the treatment of mammalian hypertension. They have the formula, R.sub.1 -A.sub.1 -S-Z, wherein Z denotes -B-A.sub.2, R.sub.1 is H or an acyl group, A.sub.1 is a carboxylic acid containing at least one amino or imino -N-, A.sub.2 is a carboxylic acid containing at least one amino or imino -N- or a lower alkyl ester or amide thereof, B is a 2-4 carbon backbone chain in mercapto linkage to S which includes a carbonyl or sulfonyl group joined in carboxamido or sulfonamido linkage, respectively, to A.sub.2. Preferably A.sub.2 includes a 4-6 membered C-N ring or a 5 membered ring of one N, one S and 3 C atoms.

  披露了新型硫醇酯化合物，它们是口服有效的血管紧张素转化酶抑制剂，用于治疗哺乳动物的 hypertension。它们具有以下公式，R.sub.1 -A.sub.1 -S-Z，其中 Z 表示 -B-A.sub.2，R.sub.1 是 H 或一个酰基团，A.sub.1 是至少含有一个氨基或亚氨基 -N- 的羧酸，A.sub.2 是至少含有一个氨基或亚氨基 -N- 的羧酸或其低级烷基酯或酰胺，B 是一个 2-4 碳骨架链，通过巯基连接到 S，并包括一个碳酰基或磺酰基团，分别通过羧酰胺或磺酰胺连接到 A.sub.2。优选的是 A.sub.2 包含一个 4-6 成员的 C-N 环或一个由一个 N、一个 S 和 3 个 C 原子组成的 5 成员环。
• [EN] KETONE INHIBITORS OF LYSINE GINGIPAIN<br/>[FR] INHIBITEURS CÉTONE DE LYSINE GINGIPAÏNE
  申请人：CORTEXYME INC

  公开号：WO2018053353A1

  公开（公告）日：2018-03-22

  The present invention provides compounds according to Formula (I) as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

  本发明提供了如下式（I）所述的化合物，以及它们用于抑制牙龈假单胞菌（Porphyromonas gingivalis）的赖氨酸基因底物蛋白酶（Kgp）的用途。还描述了牙龈蛋白酶活性探针化合物和测定牙龈蛋白酶活性的方法，以及用于治疗与牙龈假单胞菌感染相关的疾病的方法，包括阿尔茨海默病等脑部疾病。
• INHIBITORS OF LYSINE GINGIPAIN
  申请人：Cortexyme, Inc.

  公开号：US20160096830A1

  公开（公告）日：2016-04-07

  The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis , including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

  本发明通常涉及针对细菌牙龈脓红素Porphyromonas gingivalis及其蛋白酶赖氨酸龈蛋白酶（Kgp）的治疗方法，以及它们用于治疗与P. gingivalis感染相关的疾病，包括脑部疾病如阿尔茨海默病。在某些实施例中，本发明提供根据本文所述的I式化合物及其药用可接受的盐。
• Angiotensin converting enzyme inhibitors
  申请人：UNIVERSITY OF MIAMI

  公开号：EP0036713A2

  公开（公告）日：1981-09-30

  Novel inhibitors of angiotensin converting enzyme having the general formula R-A-S-Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

  公开了通式为 R-A-S-Z 的新型血管紧张素转换酶抑制剂，它们是血管紧张素转换酶的强效抑制剂，也是有用的抗高血压药物。
• Inhibitors of lysine gingipain
  申请人：Cortexyme, Inc.

  公开号：US10301301B2

  公开（公告）日：2019-05-28

  The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.

  本发明一般涉及针对牙龈卟啉单胞菌（包括其蛋白酶赖氨酸龈肽酶（Kgp））的治疗药物，及其用于治疗与牙龈卟啉单胞菌感染相关的疾病，包括脑部疾病，如阿尔茨海默氏症。在某些实施方案中，本发明提供了本文所述的根据式 I 的化合物及其药学上可接受的盐。